Updated HIV Prevention and Treatment Recommendations from the International Antiviral Society

The 2022 IAS-USA ART Guidelines give special emphasis to long-acting agents, aging, substance use disorder, disparity issues, and management of coinfection with SARS-CoV-2 and MPOX in persons living with HIV.

Sponsoring Organization: International Antiviral Society-USA

Target Audience: Infectious disease specialists, primary care providers, and public health staff

Background and Objective

An expert panel reviewed and graded recent data (January 2020–October 2022) to update the 2020 recommendations on treatment and prevention of HIV infection in adults; new issues include COVID-19 and monkeypox (MPOX) coinfections.

Key Points

Additional support is emphasized for early HIV testing and rapid initiation of therapy when circumstances allow.
Initial use of an INSTI-based regimen combined with TDF or TAF (TXF) and lamivudine or emtricitabine (XTC) is strongly recommended. The 2-drug regimen of dolutegravir + lamivudine can be a first choice if the HIV RNA le…

Reviewing Author

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes